Overview

Palbociclib Continuation Study for Participants Continuing From Pfizer-sponsored Palbociclib Clinical Studies

Status:
Not yet recruiting

Trial end date:
2026-04-19

Target enrollment:
0

Participant gender:
All

Summary

A continuation study for participants deriving clinical benefit from palbociclib parent studies

Phase:

Phase 2

Accepts Healthy Volunteers?

Details

Lead Sponsor:

Pfizer

Treatments:

Cetuximab
Fulvestrant
Letrozole
Palbociclib

Criteria

Inclusion Criteria:

- Any participant who is receiving study treatment and deriving clinical benefit as
determined by the investigator in a Pfizer-sponsored palbociclib Parent Study

- Participants must agree to follow the reproductive criteria

- Participants who are willing and able to comply with all scheduled visits, treatment
plans, and other study procedures

- Capable of giving signed informed consent which includes compliance with the
requirements and restrictions listed in the informed consent document and protocol

Exclusion Criteria:

- Any medical reason that, in the opinion of the investigator or sponsor, precludes the
participant from inclusion in the study